Introduction Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the
treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and …

Background: In patients with atrial fibrillation (AF), ventricular rate control with medications
has been found to be noninferior in preventing clinical events, compared to a strategy …

Objective To investigate whether the results of a rhythm control strategy differ according to
the duration between diagnosis of atrial fibrillation and treatment initiation. Design …

Background—Stroke is a debilitating condition with an increased risk in patients with atrial
fibrillation. Although data from clinical trials suggest that both rate and rhythm control are …

Atrial fibrillation (AF) represents the most common arrhythmia worldwide and its prevalence
exponentially increases with age. It is related to increased risk of ischemic stroke or systemic …

Despite being one of the most studied arrhythmias, there is paucity of information regarding
atrial fibrillation (AF) control in the general population and the treatment strategies utilized by …

Objectives: The study sought to evaluate clinical outcomes in clinical practice with rhythm
control versus rate control strategy for management of atrial fibrillation (AF). Background …

Background: The effectiveness of restoring the sinus rhythm by catheter ablation relative to
that of medical rate control for persistent atrial fibrillation (AF) patients with heart failure (HF) …

Heart failure (HF) is a complex clinical syndrome resulting from structural or functional
impairments of ventricular filling or ejection of blood. HF has a poor prognosis and the …

Aims There is little evidence of beta‐blocker treatment benefit in patients with heart failure
and reduced left ventricular ejection fraction (HFREF) and atrial fibrillation (AF). We …